How Long Does Ketamine Stay in Your System?

Ketamine stays in your system for roughly 10 to 20 hours, and drug testing answers a different question entirely. Urine testing detects ketamine metabolites for up to 14 days.

Chronic heavy use extends that urine window far longer, past 90 days in documented cases. Blood detects ketamine for 24 to 48 hours and saliva for around 24 hours.

Hair follicle testing reaches back roughly 90 days. The detail that matters most is that ketamine appears on no standard drug panel at all.

Key Takeaways

• Ketamine carries an elimination half-life of 2 to 4 hours, so the parent drug clears within roughly 10 to 20 hours while its metabolites remain detectable for days or weeks.
• Approximately 91% of an administered dose appears in urine across five days, and only about 20% of that is the parent drug or its major metabolites.
• Adamowicz and Kala detected ketamine for 2 days and norketamine for 14 days in the same urine samples using two different analytical methods.
• Ketamine appears on no standard 5-panel, 10-panel, or 12-panel screen and requires a dedicated ketamine assay.
• Urinary symptoms affect 26% to 30% of regular ketamine users, and regular use raises the risk of lower urinary tract symptoms three to fourfold.

Ketamine Detection Windows For Each Drug Test

Laboratories detect ketamine and norketamine for up to 14 days in urine, 24 to 48 hours in blood, around 24 hours in saliva, and up to 90 days in hair.

Test type	Detection window	Clinical notes
Urine	2 to 14 days	Chronic heavy use documented at 22 to 96 days at forensic cutoffs
Blood	24 to 48 hours	Parent drug clears faster; norketamine extends the window
Saliva	Up to 24 hours	Some laboratories report up to 48 hours
Hair follicle	Up to 90 days	Case reports document single-dose detection near four months

How long does ketamine stay in urine?

Urine detects ketamine and norketamine for 2 to 14 days after a single dose depending on the analytical method. Adamowicz and Kala measured both compounds in children given therapeutic ketamine and found ketamine detectable to 2 days by one method and 11 days by another, with norketamine reaching 14 days.

Chronic use extends the window dramatically. A case series of seven ketamine-dependent patients admitted for detoxification found urine samples remained positive for 22 to 96 days, with dehydronorketamine detectable longest at a 1 nanogram per millilitre cutoff.

How long does ketamine stay in blood?

Blood detects ketamine for approximately 24 hours and norketamine for up to 48 hours. The narrow window reflects rapid redistribution from the central nervous system into peripheral tissues after administration.

Blood testing appears in emergency medicine, impaired driving investigation, and postmortem toxicology. Employers do not use it for screening.

How long does ketamine stay in saliva and hair?

Saliva detects ketamine for around 24 hours, with some laboratories reporting up to 48 hours. Oral fluid collection is simple and can be directly observed, which suits roadside and for-cause testing.

Hair follicle testing detects ketamine across roughly 90 days with a standard 1.5-inch sample, and case reports document detection approaching four months after a single administration. That sensitivity makes hair analysis valuable in drug-facilitated assault investigations, where a person may not present for testing until weeks afterward.

How does the body break down and clear ketamine?

The liver metabolizes ketamine through cytochrome P450 enzymes and the kidneys excrete the resulting metabolites. The elimination half-life measures 2 to 4 hours, and four to five half-lives produce near-complete clearance of the parent drug within roughly 10 to 20 hours.

CYP3A4 drives the primary pathway, with CYP2B6 and CYP2C9 contributing secondarily. The main product is norketamine, an active metabolite that outlasts ketamine itself and is what most laboratories actually target.

Norketamine breaks down further into dehydronorketamine and hydroxynorketamine. These secondary metabolites carry little activity but persist in urine considerably longer than either the parent drug or norketamine.

Approximately 91% of an administered dose appears in urine over five days, and only about 20% of that recovery is parent drug or major metabolites. Hydroxylated metabolites clear through both urine and bile.

The gap between a three-hour half-life and a two-week urine window confuses most people who encounter it. The drug is gone within a day while the chemical record of it is not.

What does ketamine show up as on a drug test?

On a test designed to find it, ketamine registers as ketamine and norketamine. Laboratories typically target norketamine because it persists longer than the parent compound and remains more stable in urine.

Confirmation runs through gas chromatography or liquid chromatography mass spectrometry. An employer wanting to detect ketamine must specifically order and fund that testing rather than relying on any standard panel.

Does ketamine show up on a 5-panel or 10-panel test?

Neither panel includes ketamine. The standard 5-panel screens for amphetamines, cocaine, opiates, phencyclidine, and cannabis, and the 10-panel adds benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone.

Ketamine and phencyclidine belong to the same chemical class, which fuels a persistent assumption that ketamine triggers the PCP marker. Cross-reactivity is unreliable, and a negative PCP result rules out nothing about ketamine use.

Does ketamine show up on a 12-panel test?

Generally no, though panel composition is not standardized across laboratories. Standard 12-panel tests expand into opioid and prescription classes rather than dissociatives.

Some expanded or custom panels do carry a ketamine target, particularly in pain management, addiction treatment, probation, military, and forensic settings. Anyone subject to monitoring in those contexts should assume ketamine can be added without notice.

How long do the effects of ketamine last?

Ketamine effects last 15 to 90 minutes depending entirely on route, making it shorter acting than almost any other commonly misused substance. Bioavailability differs sharply between routes and explains most of the variation.

Route	Bioavailability	Onset	Duration of effects
Intravenous	100%	10 to 30 seconds	5 to 15 minutes at anesthetic dose
Intramuscular	93%	3 to 5 minutes	12 to 30 minutes at anesthetic dose
Intranasal	45% to 50%	10 to 15 minutes	Up to 60 minutes
Oral	16% to 29%	20 to 30 minutes	60 to 90 minutes

Do medical ketamine and Spravato show up on a drug test?

Medically administered ketamine and esketamine register on any panel configured to detect ketamine. Detection windows are broadly comparable to recreational use, adjusted for the lower doses typically involved.

Ketamine is a Schedule III controlled substance, reflecting accepted medical use alongside abuse potential. It holds FDA approval as a general anesthetic, while esketamine, marketed as Spravato, is approved for treatment-resistant depression alongside an oral antidepressant and administered under observation in certified settings. Recreationally, ketamine is used for its dissociative effects, which is why it is often discussed alongside classic hallucinogens even though its pharmacology is distinct.

Compounded and at-home ketamine products have expanded rapidly and prompted an FDA warning about the risks of use without monitoring. These products are still ketamine and produce positive results on any test configured to find them.

What affects how long ketamine stays in the body?

Dose and frequency of use drive most of the variation in ketamine clearance, amplified by the short duration that encourages repeat dosing. Route, hepatic function, and renal function account for the remainder.

Variables that lengthen or shorten ketamine detection windows:

• Dose and redosing: The dominant factor, magnified because a 15 to 60 minute experience invites repeated dosing within a single session.
• Frequency of use: Chronic use accumulates metabolites faster than the kidneys clear them, extending urine detection past 90 days in documented cases.
• Route of administration: Intravenous and intramuscular routes deliver 93% to 100% of the dose, while oral bioavailability falls to 16% to 29% through first-pass metabolism.
• Liver function: Hepatic CYP3A4 metabolism drives clearance, and chronic ketamine use itself produces liver injury that slows it further.
• Kidney function: Renal excretion removes the overwhelming majority of the dose, so impairment extends every window.
• Other substances: Drugs competing for CYP3A4 slow ketamine breakdown, and alcohol compounds sedation without changing clearance.

No detox product, supplement, or hydration strategy accelerates elimination. Heavy water intake dilutes urine enough to trigger a specimen validity flag, which prompts a repeat collection under observation.

What are the long-term risks of regular ketamine use?

Bladder damage is the signature harm of chronic ketamine use and the risk most users underestimate. Urinary symptoms affect 26% to 30% of regular users, and regular use raises the risk of lower urinary tract symptoms three to fourfold compared with non-users.

Additional documented risks of ketamine use:

• Liver injury: The FDA has warned about ketamine-associated drug-induced liver injury in a cholestatic pattern, with biliary duct dilatation reported in recurrent use.
• Severe abdominal cramping: Episodes intense enough to prompt emergency department visits are a frequent complaint among heavy users.
• Cognitive effects: Memory and executive function impairments accumulate with sustained use and partially improve with abstinence.
• Overdose risk in combination: Ketamine is potentially fatal in alcohol-intoxicated patients, and a systematic review found it involved in 79% of overdose cases and 89% of deaths where co-ingestants were present.

"The bladder damage from chronic ketamine use is the complication we watch for most closely, because it develops silently and clients often don't report symptoms until it's already significant. Our medical team screens for urinary and liver changes early in treatment rather than waiting for a client to raise it."

— Dr. Gergana Dimitrova, MD, Medical Director, South Carolina Addiction Treatment

Across clients admitted for detox at South Carolina Addiction Treatment, internal outcomes data from January 2025 to April 2026 show 99% satisfaction with medical and nursing care (4.94 out of 5), a 58% decrease in cravings by discharge, and 82% of clients who begin treatment complete it.

When does ketamine use signal a problem?

Ketamine rarely arrives alone at intake. Because ketamine produces no dangerous withdrawal on its own, the nursing assessment completed on arrival focuses on identifying the alcohol, benzodiazepine, or opioid dependence underneath, which is what determines whether medically supervised withdrawal is clinically necessary.

South Carolina Addiction Treatment accepts admissions for substances many detox programs decline, including ketamine, kratom, and nitrous oxide. The 16-bed CARF-accredited drug rehab in Simpsonville is licensed by the South Carolina Department of Public Health for both detox and residential care.

For clients whose ketamine use co-occurs with opioid dependence, medication-assisted options such as Suboxone can support recovery once detox is complete.

Many people arrive having used ketamine recreationally after encountering it therapeutically for depression, and distinguishing a pre-existing mood disorder from ketamine-driven symptoms changes the treatment plan entirely. The medical detox program provides 24-hour nursing coverage under Medical Director Gergana Dimitrova, MD.

References

1. Rosenbaum, S. B., Gupta, V., Patel, P., & Palacios, J. L. (2024). Ketamine. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470357/
2. Castellani, D., Pirola, G. M., Gubbiotti, M., Rubilotta, E., Gudaru, K., Gregori, A., & Dellabella, M. (2020). What urologists need to know about ketamine-induced uropathy: A systematic review. Neurourology and Urodynamics, 39(4), 1049–1062.
3. Dinis-Oliveira, R. J. (2017). Metabolism and metabolomics of ketamine: A toxicological approach. Forensic Sciences Research, 2(1), 2–10.
4. Chaves, T. V., Wilffert, B., & Sanchez, Z. M. (2023). Overdoses and deaths related to the use of ketamine and its analogues: A systematic review. American Journal of Drug and Alcohol Abuse, 49(2), 141–150. https://pubmed.ncbi.nlm.nih.gov/36410032/
5. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing.
6. Drug Enforcement Administration. (n.d.). Ketamine drug fact sheet. U.S. Department of Justice. https://www.dea.gov/factsheets/ketamine